Building on this work, tools can be developed to identify individuals at risk for developing immunometabolic depression (e.g., using blood tests of high-density lipoprotein and C-reactive protein levels) and target them for cholesterol-lowering or anti-inflammatory medical interventions. The gene discussed is CRP; the disease is major depressive disorder.